Argyle Capital Management adds Laboratory Corp. of America Holdings (LH) to its portfolio

Laboratory Corp. of America Holdings (LH) : Argyle Capital Management added new position in Laboratory Corp. of America Holdings during the most recent quarter end. The investment management firm now holds 1,607 shares of Laboratory Corp. of America Holdings which is valued at $221,123 , the company said in a statement filed on Jul 26, 2016 with the SEC.Laboratory Corp. of America Holdings makes up approximately 0.09% of Argyle Capital Management’s portfolio.

Other Hedge Funds, Including , Pggm Investments boosted its stake in LH in the latest quarter, The investment management firm added 1,052 additional shares and now holds a total of 80,450 shares of Laboratory Corp. of America Holdings which is valued at $11,069,920. Laboratory Corp. of America Holdings makes up approx 0.06% of Pggm Investments’s portfolio.Jlb Associates Inc reduced its stake in LH by selling 150 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 20,991 shares of LH which is valued at $2,913,971. Laboratory Corp. of America Holdings makes up approx 0.80% of Jlb Associates Inc’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in LH in the latest quarter, The investment management firm added 415 additional shares and now holds a total of 37,111 shares of Laboratory Corp. of America Holdings which is valued at $5,043,385. Laboratory Corp. of America Holdings makes up approx 0.93% of Franklin Street Advisors Inc Nc’s portfolio.

Laboratory Corp. of America Holdings opened for trading at $138.29 and hit $139.64 on the upside on Friday, eventually ending the session at $139.56, with a gain of 0.76% or 1.05 points. The heightened volatility saw the trading volume jump to 8,10,187 shares. Company has a market cap of $14,291 M.

On the company’s financial health, Laboratory Corp. of America Holdings reported $2.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.30. The company had revenue of $2382.00 million for the quarter, compared to analysts expectations of $2334.01 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.

Leave a Reply

Laboratory Corp. of America Holdings - Is it time to Sell?

Top Brokerage Firms are advising their investors on Laboratory Corp. of America Holdings. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.